Lawrence Hamann

Company: Celgene

Job title: Corporate Vice President, Chemistry

Bio:

Larry Hamann is currently Corporate Vice President and Global Head of Chemistry at Celgene, with responsibility for Medicinal and Computational Chemistry, Biochemistry, Structural and Chemical Biology and Screening. In > 27 years of drug discovery experience he has led teams responsible for more than 16 clinical stage compounds, including the FDA approved DPP4 inhibitor saxagliptin (Onglyza™) for type 2 diabetes, and first-in-class HCV NS5A inhibitor daclatasvir (Daklinza™) for hepatitis C. At Celgene, his teams have advanced a number of molecules into the clinic in oncology and autoimmune disease. Prior to Celgene, Larry was Executive Director, Global Discovery Chemistry at Novartis, overseeing programs in oncology, neuroscience, respiratory, cardiovascular, and rare genetic disease. Among the compounds from these efforts that continue to advance in clinical trials are branaplam – an investigational Phase II oral drug for treatment of Spinal Muscular Atrophy, a rare and fatal genetic disease, and LSZ102 – a Selective Estrogen Receptor Degrader (SERD) for ER+ breast cancer. Previously, Larry was at Bristol-Myers Squibb and Ligand Pharmaceuticals. Larry is co-inventor on > 70 patents and co-author on > 75 scientific publications, and serves on the NIH Study Section for Synthetic and Biological Chemistry. Larry holds a BS in Chemistry from the University of Detroit and a PhD in Organic Chemistry from the University of Michigan.